Karmic Lifesciences Revenue and Competitors
Estimated Revenue & Valuation
- Karmic Lifesciences's estimated annual revenue is currently $11.5M per year.
- Karmic Lifesciences's estimated revenue per employee is $201,000
Employee Data
- Karmic Lifesciences has 57 Employees.
- Karmic Lifesciences grew their employee count by -2% last year.
Karmic Lifesciences's People
Name | Title | Email/Phone |
---|
Karmic Lifesciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Karmic Lifesciences?
Karmic Lifesciences LLP, a new legal entity formed after acquiring assets from Karmic Labs by Cliantha Research Limited in July 2014. Karmic is a regulatory compliant, full-service Contract Research Organization headquartered in India with full global execution capabilities. Karmic provides integrated services offerings in the areas of Clinical Data Management, Biostatistics, Medical affairs and Personal healthcare services. To know more, visit us at www.karmiclifesciences.com
keywords:N/AN/A
Total Funding
57
Number of Employees
$11.5M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Karmic Lifesciences News
2022-04-06 - 2022 Graduate Exhibition Award winners announced
Health and life sciences ... hospitality management, "Instant Karma: the role of karmic-investment mindset in charitable giving".
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.4M | 57 | 2% | N/A |
#2 | $4M | 61 | -10% | N/A |
#3 | $5.2M | 64 | -2% | N/A |
#4 | $8.2M | 65 | 25% | N/A |
#5 | $12.3M | 65 | 30% | N/A |